Accueil   Diary - News   All news POXEL and ENYO Pharma sign license agreement for POXEL’s FXR Agonist Program

POXEL and ENYO Pharma sign license agreement for POXEL’s FXR Agonist Program

POXEL SA, a biopharmaceutical company developing innovative drugs to treat type 2 diabetes, and ENYO Pharma SAS, a newly-formed company focused on the treatment of acute and chronic viral infections, today announced the signing of a license agreement under which ENYO will gain access to Poxel’s FXR (farnesoid X receptor) agonist compounds for infection-related indications with Poxel retaining rights for cardiovascular and metabolic indications among others. No financial terms of the agreement have been disclosed.

 

 

Read the press release